Faron Pharmaceuticals (AIM:FARN) (OTC:FPHAF) CEO, Markku Jalkanen presents at the Proactive One2One Investor Forum – October 6th 2022
Faron Pharmaceuticals Limited is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs.
The company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage.
